Literature DB >> 6191738

Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus.

H Kida, R G Webster, R Yanagawa.   

Abstract

A/seal/Massachusetts/1/80 (H7N7) influenza virus caused maximal hemolysis at pH 5.9 Monoclonal antibodies to each of the four nonoverlapping antigenic areas on the hemagglutinin molecule of the virus inhibited the hemolysis whereas those belonging to two of the groups did not inhibit hemagglutination of the virus. Hemolysis also occurred when the virus was incubated at pH 5.9 prior to addition of erythrocytes. Such hemolysis caused by acid-treated virus was inhibited with the antibodies as well. At pH 5.9, hemagglutination of neither intact virus nor hemagglutinin rosettes was inhibited with any of the monoclonal antibodies, indicating conformational change in the hemagglutinin molecule, at this pH. On the other hand, hemagglutination-inhibition was observed when the antigens were incubated with the monoclonal antibodies at pH 7.0 and then the pH was later shifted to 5.9, suggesting that antibody-binding interferes with the conformational change in the hemagglutinin molecule at pH 5.9. The present findings indicate that antibodies to the hemagglutinin of influenza virus can inhibit virus-induced hemolysis by blocking conformational change in the hemagglutinin molecule and blocking later step of fusion than the conformational change, in addition to blocking attachment of virus to the receptor of erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191738     DOI: 10.1007/bf01311693

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  15 in total

1.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

Review 2.  The structure and function of paramyxovirus glycoproteins.

Authors:  H D Klenk; Y Nagai; R Rott; C Nicolau
Journal:  Med Microbiol Immunol       Date:  1977       Impact factor: 3.402

3.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

4.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus.

Authors:  H Kida; L E Brown; R G Webster
Journal:  Virology       Date:  1982-10-15       Impact factor: 3.616

5.  pH-dependent hemolysis by influenza, Semliki, Forest virus, and Sendai virus.

Authors:  J Lenard; D K Miller
Journal:  Virology       Date:  1981-04-30       Impact factor: 3.616

6.  Characterization of an influenza A virus from seals.

Authors:  R G Webster; V S Hinshaw; W J Bean; K L Van Wyke; J R Geraci; D J St Aubin; G Petursson
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

7.  Influenza viruses cause hemolysis and fusion of cells.

Authors:  R T Huang; R Rott; H D Klenk
Journal:  Virology       Date:  1981-04-15       Impact factor: 3.616

8.  Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus.

Authors:  R G Webster; W G Laver
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

9.  Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity.

Authors:  R D Possee; G C Schild; N J Dimmock
Journal:  J Gen Virol       Date:  1982-02       Impact factor: 3.891

10.  Infectious entry pathway of influenza virus in a canine kidney cell line.

Authors:  K S Matlin; H Reggio; A Helenius; K Simons
Journal:  J Cell Biol       Date:  1981-12       Impact factor: 10.539

View more
  18 in total

1.  Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity?

Authors:  S Yoden; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

2.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

3.  Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1.

Authors:  H Ochiai; M Kurokawa; K Hayashi; S Niwayama
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Optimum length and flexibility of reovirus attachment protein σ1 are required for efficient viral infection.

Authors:  Magdalena Bokiej; Kristen M Ogden; Mine Ikizler; Dirk M Reiter; Thilo Stehle; Terence S Dermody
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Antigenic mapping and functional analysis of the F protein of Newcastle disease virus using monoclonal antibodies.

Authors:  G Abenes; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

Review 6.  Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Authors:  Manon M J Cox; Ruvim Izikson; Penny Post; Lisa Dunkle
Journal:  Ther Adv Vaccines       Date:  2015-07

7.  Influenza virus strains with a fusion threshold of pH 5.5 or lower are inhibited by amantadine. Brief report.

Authors:  W E Beyer; R W Ruigrok; H van Driel; N Masurel
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

Authors:  B E Johansson; D J Bucher; E D Kilbourne
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

9.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Authors:  David L Gordon; Dimitar Sajkov; Richard J Woodman; Yoshikazu Honda-Okubo; Manon M J Cox; Susanne Heinzel; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-17       Impact factor: 3.641

10.  Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes.

Authors:  Yurie Motohashi; Manabu Igarashi; Masatoshi Okamatsu; Takeshi Noshi; Yoshihiro Sakoda; Naoki Yamamoto; Kimihito Ito; Ryu Yoshida; Hiroshi Kida
Journal:  Virol J       Date:  2013-04-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.